Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Econ ; 17(6): 435-41, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24716650

ABSTRACT

INTRODUCTION: Myelofibrosis is a non-frequent chronic myeloproliferative Philadelphia-negative chromosome neoplasm. It is a heavy incapacitating orphan disease and associated with high morbidity and mortality. In this context, indirect and non-medical costs are expected to be high. The main objective of this project is to estimate the economic burden of this disease in Spain. METHODS: Thirty-three patients with a diagnosis of myelofibrosis for at least 1 year participated in a questionnaire in three Spanish centers. The study consisted of analyzing in various aspects the cost and impact of the disease; indeed, daily life time limitations with a need of informal care, symtomatology. Additionally, information concerning the clinical management of the disease was collected through a focus group of eight experts. RESULTS: The mean age was 65 years. 15 of 33 patients were at their productive stage. Six had difficulties at work and eight have received informal care. Bone and muscular pain were the main symptoms of patients (72%). The estimated global indirect and non-medical costs of the disease were 86,315€ per patient (20% working and 80% informal care), which reached 104,153€ at productive stage patients (45%) and 168,459€ for more symptomatic patients. CONCLUSIONS: The economic burden of indirect and non-medical costs of myelofibrosis are important (15,142€/annual) as a result, and should be considered in economic evaluation, as well as in preventive plans for patients and caregivers, despite the fact that studies with larger numbers of patients should be done.


Subject(s)
Disabled Persons/statistics & numerical data , Primary Myelofibrosis/economics , Activities of Daily Living , Aged , Caregivers/economics , Caregivers/statistics & numerical data , Cost of Illness , Costs and Cost Analysis , Female , Humans , Male , Middle Aged , Mobility Limitation , Pain/etiology , Primary Myelofibrosis/complications , Primary Myelofibrosis/psychology , Quality of Life , Socioeconomic Factors , Spain
2.
Comp Biochem Physiol A Mol Integr Physiol ; 166(3): 399-405, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23871878

ABSTRACT

Sources of blood glucose in European seabass (initial weight 218.0±43.0g; mean±S.D., n=18) were quantified by supplementing seawater with deuterated water (5%-(2)H2O) for 72h and analyzing blood glucose (2)H-enrichments by (2)H NMR. Three different nutritional states were studied: continuously fed, 21-day of fast and 21-day fast followed by 3days of refeeding. Plasma glucose levels (mM) were 10.7±6.3 (fed), 4.8±1.2 (fasted), and 9.3±1.4 (refed) (means±S.D., n=6), showing poor glycemic control. For all conditions, (2)H-enrichment of glucose position 5 was equivalent to that of position 2 indicating that blood glucose appearance from endogenous glucose 6-phosphate (G6P) was derived by gluconeogenesis. G6P-derived glucose accounted for 65±7% and 44±10% of blood glucose appearance in fed and refed fish, respectively, with the unlabeled fraction assumed to be derived from dietary carbohydrate (35±7% and 56±10%, respectively). For 21-day fasted fish, blood glucose appearance also had significant contributions from unlabeled glucose (52±16%) despite the unavailability of dietary carbohydrates. To assess the role of hepatic enzymes in glycemic control, activity and mRNA levels of hepatic glucokinase (GK) and glucose 6-phosphatase (G6Pase) were assessed. Both G6Pase activity and expression declined with fasting indicating the absence of a classical counter-regulatory stimulation of hepatic glucose production in response to declining glucose levels. GK activities were basal during fed and fasted conditions, but were strongly stimulated by refeeding. Overall, hepatic G6Pase and GK showed limited capacity in regulating glucose levels between feeding and fasting states.


Subject(s)
Bass/metabolism , Food Deprivation/physiology , Animals , Blood Glucose , Fish Proteins/genetics , Fish Proteins/metabolism , Gene Expression , Gene Expression Regulation, Enzymologic , Glucokinase/genetics , Glucokinase/metabolism , Gluconeogenesis , Glucose-6-Phosphatase/genetics , Glucose-6-Phosphatase/metabolism , Glycogenolysis , Liver/enzymology , Muscle, Skeletal/metabolism
3.
J Mol Endocrinol ; 45(3): 119-32, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20573775

ABSTRACT

Alanine aminotransferase (Alt) provides a molecular link between carbohydrate and amino acid metabolism. In the cell context, the predominant Alt isozyme is located in the cytosol. To gain insight into the transcriptional regulation of the cytosolic alt gene (calt), we cloned and characterized the calt promoter from gilthead sea bream (Sparus aurata). Transient transfection of sea bass larvae cells with deleted calt promoter constructs and electrophoretic mobility shift assays allowed us to identify p300 and c-Myb as new factors in the transcriptional regulation of calt expression. Transfection studies carried out with an acetylase-deficient mutant p300 (p300DY) revealed that the acetyltransferase activity of p300 is essential for the p300-mediated transcriptional activation of S. aurata calt. We had previously found up-regulation of liver cAlt2, an alternatively spliced isoform of calt, under gluconeogenic conditions and in streptozotocin (STZ)-treated S. aurata. Quantitative RT-PCR assays showed that increased p300 and c-Myb mRNA levels in the liver of starved S. aurata contribute to enhancing the transcription of cAlt2. Consistently, the administration of insulin decreased both p300 and c-Myb expression. The mRNA levels of p300 and c-Myb were also analyzed in the liver of STZ-induced diabetic S. aurata. Treatment with STZ increased the expression of p300, whereas it decreased c-Myb. Our findings suggest an involvement of p300 and c-Myb in up-regulation of cAlt2 in the liver of S. aurata under starvation. In addition, these results provide evidence for a role of p300 in diabetes.


Subject(s)
Alanine Transaminase/genetics , Cytosol/enzymology , Promoter Regions, Genetic , Proto-Oncogene Proteins c-myb/metabolism , Sea Bream/genetics , Transcriptional Activation/genetics , p300-CBP Transcription Factors/metabolism , 5' Flanking Region/genetics , Animals , Base Sequence , Bass , Cloning, Molecular , Consensus Sequence/genetics , Cytosol/drug effects , Gene Expression Regulation, Enzymologic/drug effects , Histone Acetyltransferases , Insulin/pharmacology , Liver/metabolism , Molecular Sequence Data , Multiprotein Complexes/metabolism , Mutation/genetics , Protein Binding/drug effects , Response Elements/genetics , Sequence Deletion
SELECTION OF CITATIONS
SEARCH DETAIL
...